Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar symbols : Amgn save search
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
Biosimilar Hormones Global Market Report 2024 - Niche Sectors Record Notable Market Contributions
Published: 2024-02-14 (Crawled : 03:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
biosimilar report global market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.54 1.05% 0.74% 190K
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.18 1.57% 1.16% 11K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
United States Biosimilar Market Report 2023: Sector is Expected to Reach $50.68 Billion in 2027 at a CAGR of 40.17%
Published: 2023-06-30 (Crawled : 19:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
biosimilar report expected reach market
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Published: 2023-05-25 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -0.89%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: -1.2%
biosimilar authorization ema
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
BGNE | $144.12 3.69% 3.48% 190K
|
Health Technology
|
| O: -0.74%
H: 1.16%
C: 0.69%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: -0.58%
humira biosimilar
Biosimilar Therapeutic Peptides Global Market to Reach $3.5 Billion by 2026 at a CAGR of 30.3%
Published: 2022-12-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.74%
H: 8.46%
C: 8.46%
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.97%
H: 0.05%
C: 0.05%
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -0.85%
H: 0.46%
C: -0.17%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.03%
H: 0.26%
C: -0.27%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.33%
H: 0.56%
C: -0.89%
global biosimilar market
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BGNE | $144.12 3.69% 3.48% 190K
|
Health Technology
|
| O: -0.57%
H: 1.88%
C: 0.59%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -0.9%
soliris candidate biosimilar positive results study
US Biosimilar Market Report 2022: Rising Prevalence of Cancer & Increasing Health Expenditure Fueling Growth
Published: 2022-07-22 (Crawled : 17:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.78%
H: 0.0%
C: -0.1%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.37%
H: 0.52%
C: -0.39%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.42%
H: 0.94%
C: -0.34%
biosimilar report health cancer growth market
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
BGNE | $144.12 3.69% 3.48% 190K
|
Health Technology
|
| O: 7.48%
H: 0.45%
C: -4.8%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.32%
H: 0.2%
C: -1.16%
rituxan fda biosimilar
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $144.12 3.69% 3.48% 190K
|
Health Technology
|
| O: -1.9%
H: 0.12%
C: -3.78%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
stelara biosimilar positive results phase 3 topline
Biosimilars Market by Product, Indication and Region - Global Forecast to 2026
Published: 2021-11-10 (Crawled : 19:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.26%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
biosimilar
Biosimilars Market by Application and Geography | Global Forecast to 2025 | 17,000+ Technavio Research Reports
Published: 2021-09-22 (Crawled : 00:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: 0.38%
H: 1.5%
C: 0.3%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.92%
H: 0.5%
C: 0.01%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: 1.51%
H: 2.09%
C: -0.17%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.53%
H: 1.43%
C: 1.2%
research application biosimilar
Amgen Releases 8th Edition of Biosimilar Trends Report
Published: 2021-09-22 (Crawled : 13:00) - prnewswire.com
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -1.35%
biosimilar
Global Biosimilar Monoclonal Antibodies (mAbs) Market in Pharmaceuticals Industry|Discover Company Insights in Technavio
Published: 2021-07-24 (Crawled : 00:20) - prnewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
| Email alert
Add to watchlist
monoclonal antibodies antibody biosimilar
Biosimilars Market to reach a value of USD 31.40 billion through 2025|Technavio
Published: 2021-07-16 (Crawled : 04:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: -0.07%
H: 0.29%
C: -0.79%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.84%
H: 0.05%
C: -0.35%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: -1.28%
H: 2.2%
C: 0.2%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.59%
H: 0.58%
C: -0.05%
biosimilar
Global Erythropoietin Drugs Market Research Report 2021-2027: Biologics, Biosimilars, Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa
Published: 2021-07-07 (Crawled : 16:00) - prnewswire.com
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.17%
H: 0.09%
C: -0.35%
drug research biosimilar
Global $3.12 Billion Trastuzumab Biosimilars Markets, 2015-2019, 2019-2023, 2025F, 2030F
Published: 2021-05-11 (Crawled : 19:00) - prnewswire.com
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -0.35%
H: 0.92%
C: -0.23%
biosimilar
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.